In a real-world registry of patients with atrial fibrillation treated with a pulsed field ablation catheter, the system was associated with favorable 30-day outcomes, researchers reported at Heart Rhythm 2024. Lucas V. A. Boersma, MD, PhD, FESC, professor of Innovative Transcatheter Treatments for Cardiac Arrhythmias at the University of Amsterdam’s Faculty of Medicine and head of the
In patients with heterozygous familial hypercholesterolemia already taking maximally tolerated lipid-lowering medication, resmetirom lowered LDL, triglycerides, apolipoprotein B and lipoprotein(a) levels vs. placebo, researchers reported.“Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant genetic disorder, with an estimated prevalence of approximately one in 200 to
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium (BUSINESS WIRE) The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVI.
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress The Janssen Pharmaceutical Companies of Johnson Johnson today announced primary results
ABBVie today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® plus VENCLEXTA ® VENCLYXTO ® versus chlorambucil plus obinutuzumab for first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had active disease requiring treatment per the International Workshop on CLL criteria. The study met its primary …
ABBVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® (ibrutinib) plus VENCLEXTA ® VENCLYXTO ® (venetoclax) (I+V) versus chlorambucil plus obinutuzumab (C+O) for first-line treatment in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had active disease requiring treatment per the International Workshop on CLL (iwCLL) criteria. The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review c